ERBB2 and breast cancer: Similarly, a decrease of CD14+ monocytes was also observed in co-cultures of HER2+ BC cells with PBMC treated with trastuzumab and FAP-IL-2v (an engineered IL-2 variant), a therapeutic combination being evaluated in clinical trials (36).